Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (a foreign private issuer) covers the financial year ended 30 June 2012, with the report dated 31 August 2012. Prana is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative disorders, specifically Alzheimer's disease (AD) and Huntington's disease (HD), utilizing metal-protein attenuation technology. The company is headquartered in Melbourne, Australia, and lists on the NASDAQ Capital Market via American Depository Receipts (ADRs).
Key Financial Metrics
| Metric | Year Ended 30 June 2012 | Year Ended 30 June 2011 |
|---|---|---|
| Revenue (Interest income) | A$186,664 | A$156,135 |
| Net Loss | (A$5,241,544) | (A$6,431,185) |
| Loss Per Share (Basic & Diluted) | (1.82) cents | (2.60) cents |
| Operating Cash Flow | (A$6,844,594) | (A$4,558,415) |
| Cash and Cash Equivalents (End of Period) | A$5,636,469 | A$8,838,245 |
| Total Assets | A$7,341,868 | A$9,010,952 |
| Total Liabilities | A$1,720,496 | A$2,079,750 |
| Net Tangible Assets per Share | 1.89 cents | 2.52 cents |
Other Income: A$2,340,851 (2011: A$6,785), primarily driven by a A$2.24 million R&D tax concession and a A$93,514 grant from the Michael J. Fox Foundation.
Debt: The company reported no borrowings in the cash flow statement for the period. Total liabilities consist mainly of trade payables, provisions, and unearned income.
Material Changes vs. Prior Period
- Reduced Net Loss: The net loss decreased by 18.5% to A$5.24 million, primarily due to the recognition of the Australian Government R&D tax incentive (A$2.24 million) which was not present in the prior year.
- Increased R&D Spend: Research and development expenses increased significantly to A$4.23 million (2011: A$2.76 million) as the company advanced clinical trials.
- Cash Burn: Operating cash outflows increased to A$6.84 million (2011: A$4.56 million), reflecting higher operational costs. Total cash reserves decreased by approximately A$3.2 million during the year.
- Equity Issuance: The company raised approximately A$3.89 million through the issuance of shares and ADRs during the year, compared to A$7.59 million in the prior year.
Outlook, Management Commentary, and Risks
Clinical Progress
- Huntington's Disease (PBT2): The "Reach2HD" Phase IIa trial received FDA approval in January 2012. Patient enrollment began in April 2012 across up to 20 sites in the US and Australia.
- Alzheimer's Disease (PBT2): The "IMAGINE" Phase II imaging trial commenced in March 2012, enrolling 40 patients to assess brain amyloid deposits using PET imaging. This extends a previous successful 12-week study to 12 months.
- Parkinson's Disease (PBT434): Pre-clinical characterization is ongoing with support from a Michael J. Fox Foundation grant. A US patent allowance was received in November 2011.
Liquidity and Funding
Management notes that the company has contractual obligations of approximately A$7.5 million for the Huntington's trial and A$0.7 million for the Alzheimer's trial. While A$1 million has been incurred, the completion of these trials is dependent on raising additional funding. The company maintains an "at-the-market" (ATM) facility to sell ADRs and sold an additional A$0.78 million worth of ADRs in August 2012.
Risks and Contingencies
- Going Concern: The financial statements are prepared on a going concern basis, contingent on the successful raising of additional funds. If funding is not secured, the company may need to curtail planned expenditure.
- Forward-Looking Statements: The report contains predictive statements regarding clinical trial outcomes and funding, which are subject to significant risks and uncertainties.
- Legal: No contingent liabilities or legal proceedings were reported as of the reporting date.
Investor Verification Checklist
- Verify the status and enrollment rates of the "Reach2HD" and "IMAGINE" clinical trials to assess the timeline for potential data readouts.
- Monitor the utilization of the ATM facility and the company's ability to raise the estimated A$7.5 million required for the Huntington's trial.
- Review the sustainability of the cash burn rate (approx. A$6.8m/year) against current cash reserves (A$5.6m) to estimate the runway without further capital raises.
- Confirm the continued eligibility and receipt of the Australian R&D tax incentive, which significantly reduced the reported net loss.
- Check for any updates on the PBT434 Parkinson's program and the status of the US patent.